Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.61 |
| ▸ | EGFR | P00533 | 11/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.61 |
| ▸ | SRC | P12931 | 3/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968493 | 0.87 | MAP2K1 (0.68) | MAP2K1EGFRERBB2SRC | |
| SCHEMBL2970665 | 0.81 | MAP2K1 (0.73) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL2976794 | 0.80 | MAP2K1 (0.52) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL2967767 | 0.78 | MAP2K1 (0.71) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL6185084 | 0.77 | SRC (0.83) | MAP2K1EGFRERBB2SRC | |
| SCHEMBL6382185 | 0.77 | MAP2K1 (1.00) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL2977148 | 0.76 | SRC (0.64) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL6381464 | 0.76 | EGFR (1.00) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL28756490 | 0.76 | MAP2K1 (0.95) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL27614725 | 0.75 | SRC (0.79) | EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0788554-B1 | SEQUENCE ANALYSIS OF SACCHARIDE MATERIAL | CANCER RES CAMPAIGN TECH (GB) | 2000-01-12 | — | — | EP | claimed |
| EP-0355831-B1 | Purification of glycosaminoglycan degrading enzymes | SEIKAGAKU KOGYO CO LTD (JP) | 1994-01-26 | — | — | EP | claimed |
| US-5198355-A | PURIFICATION OF GLYCOSAMINOGLYCAN DEGRADING ENZYMES WITH A SULFATED POLYSACCHARIDE | SEIKAGAKU KOGYO CO., LTD. (JP) | 1993-03-30 | — | — | US | claimed |
| EP-0355831-A2 | Purification of glycosaminoglycan degrading enzymes | SEIKAGAKU KOGYO CO., LTD. (JP) | 1990-02-28 | — | — | EP | claimed |
| CN-114746556-A | Compositions and methods for treating mountain phillips disease and other disorders | 利索基因公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20100291099-A1 | NOVEL 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 AND 32222 MOLECULES AND USES THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7776577-B2 | Ubiquitin protease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7767671-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090269350-A1 | Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC1C, NARC 1A, NARC 25, 86604 and 32222 molecules and uses therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2009-03-05 | — | — | US | disclosed |
| US-7482147-B2 | Ubiquitin protease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7449460-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| US-6767727-B2 | FOR TREATMENT OF GENETIC DISORDERS; TARGETS FOR COMPETITIVE BINDING ASSAYS; DRUG SCREENING | MILLENNIUM PHARMACEUTICALS, INC. | 2004-07-27 | — | — | US | disclosed |
| US-20040009553-A1 | Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-20030162279-A1 | 22438, 23553, 25278, and 26212 novel human sulfatases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| US-6534302-B1 | Isolated nucleic acid molecule having specified nucleotide sequence or cDNA insert of specified plasmid, which encodes sulfatase, or its complement, or which encodes polypeptide having specified amino acid sequence | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| WO-2001055411-A9 | HUMAN SULFATASES | MILLENNIUM PHARM INC (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2001055411-A2 | HUMAN SULFATASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
| US-5198355-A | PURIFICATION OF GLYCOSAMINOGLYCAN DEGRADING ENZYMES WITH A SULFATED POLYSACCHARIDE | SEIKAGAKU KOGYO CO., LTD. (JP) | 1993-03-30 | — | — | US | disclosed |
| EP-0355831-A2 | Purification of glycosaminoglycan degrading enzymes | SEIKAGAKU KOGYO CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | RAF1, KRAS, NRAS | MAP2K1 89/4885EGFR 895/4885ERBB2 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.